CCME Global Share Price & Earnings Call Analysis
- Market cap
- ₹157 Cr
- ROE
- -2.92%
- Price to sales
- 3924.20
- Debt to equity
- 0.00
- 52W high / low
- ₹185 / ₹27.5
- EBITDA margin
- -2075.00%
- Net profit margin
- -1775.00%
- Promoter holding
- 74.35%
- Sales (last year)
- ₹0 Cr
CCME Global Ltd, formerly Genesis IBRC India Ltd and SSK Lifestyles Ltd, is transitioning from a non-operational biotechnology business towards FMCG, commodities, and minerals trading, manufacturing, and import-export activities under new management.[1]
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹480 Cr | 19.1 | |
| 2 | 40%+ | Up 0–2% | ₹212 Cr | 16.1 | |
| 3 | 40%+ | Flat | ₹17,925 Cr | — | |
| 4 | 40%+ | Flat | ₹5,223 Cr | 39.1 | |
| 5 | 40%+ | Flat | ₹4,268 Cr | — | |
| 6 | 40%+ | Flat | ₹40 Cr | — |
Sign up free to see every company in the sector ranking and track CCME Global.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingCCME Global announcements
All announcements →- Fundraise / allotmentMajor developmentCCME Global allots 15,08,42,244 shares; Interlink a subsidiary, CCME UAE an associate
- Fundraise / allotmentMajor developmentCCME Global Limited announces allotment of shares for acquisitions and preferential issues
Financials of CCME Global
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of CCME Global
Quarterly Results
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses + | 0.02 | 0.05 | 0.06 | 0.02 | 0.02 | 3.69 | 0.10 | 0.02 | 0.03 | 0.02 | 0.12 | 0.06 | 0.03 |
| Operating Profit | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 | -0.06 | -0.03 |
| OPM % | 99.46% | ||||||||||||
| Other Income + | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 | -0.06 | -0.03 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit + | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 | -0.06 | -0.03 |
| EPS in Rs | -0.02 | -0.04 | -0.05 | -0.02 | -0.02 | -2.84 | -0.08 | 2.81 | -0.02 | -0.02 | -0.09 | -0.05 | -0.02 |
Financials of CCME Global
Profit & Loss
Annual income statement trend
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0.39 | 0.78 | 0.00 | 0.00 | 0.29 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses + | 0.55 | 0.93 | 0.07 | 0.07 | 0.49 | 0.10 | 0.10 | 0.12 | 0.12 | 0.14 | 3.80 | 0.17 | 0.23 |
| Operating Profit | -0.16 | -0.15 | -0.07 | -0.07 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | -0.17 | -0.23 |
| OPM % | -41.03% | -19.23% | -68.97% | -100.00% | 95.37% | ||||||||
| Other Income + | 0.01 | -0.09 | 0.42 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.18 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.33 | -0.45 | 0.35 | 0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | -0.23 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit + | -0.33 | -0.44 | 0.35 | 0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | -0.23 |
| EPS in Rs | -1.09 | -0.62 | 0.36 | 0.00 | -0.15 | -0.04 | -0.08 | -0.09 | -0.09 | -0.11 | -2.92 | 2.69 | -0.18 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of CCME Global
Balance Sheet
Capital structure and asset base
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.02 | 7.12 | 9.74 | 10.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 |
| Reserves | -3.25 | -3.70 | -3.35 | -3.35 | -3.55 | -3.70 | -3.80 | -3.92 | -4.04 | -4.17 | -7.97 | -4.47 | -4.65 |
| Borrowings + | 0.61 | 0.17 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities + | 0.90 | 0.93 | 0.51 | 0.03 | 0.07 | 0.08 | 0.12 | 0.12 | 0.13 | 0.14 | 0.18 | 0.30 | 0.16 |
| Total Liabilities | 1.28 | 4.52 | 7.10 | 6.68 | 9.52 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 |
| Fixed Assets + | 1.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 4.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets + | 0.18 | 4.52 | 7.10 | 6.68 | 4.86 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 |
| Total Assets | 1.28 | 4.52 | 7.10 | 6.68 | 9.52 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 |
Financials of CCME Global
Cash Flows
Operating, investing and financing cash movement
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 4.98 | -4.86 | -2.64 | -0.25 | 1.68 | -4.69 | 0.01 | -0.12 | -0.12 | -0.09 | 0.00 | 0.00 |
| Cash from Investing Activity + | 0.00 | 0.77 | 0.00 | 0.00 | -4.66 | 4.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activity + | 0.71 | 4.10 | 2.62 | 0.26 | 3.00 | 0.00 | 0.00 | 0.12 | 0.12 | 0.09 | 0.00 | 0.00 |
| Net Cash Flow | 5.69 | 0.01 | -0.02 | 0.01 | 0.02 | -0.03 | 0.01 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Free Cash Flow | 4.98 | -4.09 | -2.64 | -0.25 | 1.68 | -4.69 | 0.01 | -0.12 | -0.12 | -0.09 | 0.00 | 0.00 |
| CFO/OP | -3,112% | 3,240% | 3,771% | 357% | -840% | 9,380% | -10% | 100% | 100% | 64% | 0% | 0% |
Financials of CCME Global
Ratios
Working capital efficiency and return ratios
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28.08 | 229.29 | 62.93 | 292.00 | ||||||||
| Inventory Days | 104.29 | 0.00 | 0.00 | |||||||||
| Days Payable | 156.43 | |||||||||||
| Cash Conversion Cycle | -24.07 | 229.29 | 62.93 | 292.00 | ||||||||
| Working Capital Days | -1,272.82 | 1,586.35 | 5,991.03 | 67,890.00 | ||||||||
| ROCE % | -60.55% | -16.62% | 6.88% | 0.00% | -2.48% | -0.53% | -1.08% | -1.31% | -1.33% | -1.57% | -54.83% | 51.62% |
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.